The effects of fructose-1,6-bisphosphate and dexamethasone on acute inflammation and T-cell proliferation

Inflammation Research

Volumn 55, Issue 8, 2006, Pages 354-358

  Pestana Lopes, R ^a   Lunardelli, A ^a   Preissler, T ^a   Leite, C E ^a   Alves Filho, J C F ^b   Bordignon Nunes, F ^a   Rodrigues De Oliveira, J ^a   Bauer, M E ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Fructose 1,6 bisphosphate; Glucocorticoids; Human T lymphocytes; Inflammation; Pleurisy

Indexed keywords

DEXAMETHASONE; FRUCTOSE 1,6 BISPHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; INFLAMMATION; MONONUCLEAR CELL; NEUTROPHIL; NONHUMAN; PLEURA CAVITY; PLEURISY; RAT; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARRAGEENAN; CELL PROLIFERATION; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRUCTOSEDIPHOSPHATES; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; PLEURISY; RATS; RATS, WISTAR; T-LYMPHOCYTES;

EID: 33748765598     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-006-6044-8     Document Type: Article

References (31)

1. Kirtley ME, McKay M. Fructose-1,6-bisphosphate, a regulator of metabolism. Mol Cell Biochem 1977; 18: 141-9.
2. De Oliveira JR, Rosa JL, Ambrosio S, Bartrons R. Effect of galactosamine on hepatic carbohydrate metabolism: protective role of fructose 1,6-bisphosphate. Hepatology 1992; 15: 1147-53.
3. Didlake R, Kirchner KA, Lewin J, Bower JD, Markov A. Protection from ischemic renal injury by fructose-1,6-diphosphate infusion in the rat. Circ Shock 1985; 16: 205-12.
4. Farias LA, Smith EE, Markov AK. Prevention of ischemic-hypoxic brain injury and death in rabbits with fructose-1,6-diphosphate. Stroke 1990; 21: 606-13.
5. Markov AK, Turner MD, Oglethorpe N, Neely WA, Hellems HK. Fructose-1,6-diphosphate: an agent for treatment of experimental endotoxin shock. Surgery 1981; 90: 482-8.
6. Zhang JN, Zhang FM, Ma WS, Forrester T. Protective effect of exogenous fructose-1,6-diphosphate in cardiogenic shock. Cardiovasc Res 1988; 22: 927-32.
7. Roig T, De Oliveira JR, Bartons R, Bermudez J. Fructose 1,6-bisphosphate protects against D-galactosamine toxicity in isolated rat hepatocytes. Am J Physiol 1994; 266: 1722-8.
8. Fortes Aiub CA, Bortolini R, Arrieira Azambuja A, Alves Filho JC, Bordignon Nunes F, Rodrigues de Oliveira J. Alterations in the indexes of apoptosis and necrosis induced by galactosamine in the liver of Wistar rats treated with fructose-1,6-bisphosphate. Hepatol Res 2003; 25: 83-91.
9. Nunes FB, Graziottin CM, Alves Filho JC, Lunardelli A, Pires MG, Wachter PH, et al. An assessment of fructose-1,6-bisphosphate as an antimicrobial and anti-inflammatory agent in sepsis. Pharmacol Res 2003; 47: 35-41.
10. Markov AK, Causey AL, Didlake RH, Lemos LB. Prevention of alpha-naphthylthiourea-induced pulmonary edema with fructose-1,6-diphosphate. Exp Lung Res 2002; 28: 285-99.
11. Planas ME, Sanchez S, Gonzalez P, Rodrigues de Oliveira J, Bartrons R. Protective effect of fructose 1,6-bisphosphate against carrageenan-induced inflammation. Eur J Pharmacol 1993; 237: 251-5.
12. Alves Filho JC, Santos RC, Castaman TA, de Oliveira JR. Antiinflammatory effects of fructose-1,6-bisphosphate on carrageenan-induced pleurisy in rat. Pharmacol Res 2004; 49: 245-8.
13. Bordignon Nunes F, Meier Graziottin C, Alves Filho JC, Lunardelli A, Caberlon E, Peres A, et al. Immunomodulatory effect of fructose-1,6-bisphosphate on T-lymphocytes. Int Immunopharmacol 2003; 3: 267-72.
14. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000; 21: 55-89.
15. Juruena MF, Cleare AJ, Bauer ME, Pariante CM. Molecular mechanisms of glucocorticoid receptor sensitivity and relevance to affective disorders. Acta Neuropsychiatrica 2003; 15: 354-67.
16. Alesci S, De Martino MU, Ilias I, Gold PW, Chrousos GP. Glucocorticoid-induced osteoporosis: from basic mechanisms to clinical aspects. Neuroimmunomodulation 2005; 12: 1-19.
17. McDonough RP, Doucette WR. Kumbera P, Klepser DG. An evaluation of managing and educating patients on the risk of glucocorticoid-induced osteoporosis. Value Health 2005; 8: 24-31.
18. Bernal-Mizrachi C, Weng S, Feng C, Finck BN, Knutsen RH, Leone TC, et al. Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice. Nat Med 2003; 9: 1069-75.
19. Willi SM, Kennedy A, Brant BP, Wallace P, Rogers NL, Garvey WT. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes. Diabetes Res Clin Pract 2002; 58: 87-96.
20. Brown ES, Chandler PA. Mood and Cognitive Changes During Systemic Corticosteroid Therapy. Prim Care Companion J Clin Psychiatry 2001; 3: 17-21.
21. Mahachoklertwattana P, Vilaiyuk S, Hongeng S, Okascharoen C. Suppression of adrenal function in children with acute lymphoblastic leukemia following induction therapy with corticosteroid and other cytotoxic agents. J Pediatr 2004; 144: 736-40.
22. Perry RJ, Findlay CA, Donaldson MD. Cushing's syndrome, growth impairment, and occult adrenal suppression associated with intranasal steroids. Arch Dis Child 2002; 87: 45-8.
23. Bauer ME, Papadopoulos A, Poon L, Perks P, Lightman S, Checkley S, et al. Altered glucocorticoid immunoregulation in treatment resistant depression. Psychoneuroendocrinol. 2003; 28: 49-65.
24. Norbiato G, Bevilacqua M, Vago T, Clerici M. Glucocorticoid resistance and the immune function in the immunodeficiency syndrome. Ann N Y Acad Sci 1998; 840: 835-47.
25. Corrigan C, Bungre J, Assoufi B, Cooper A, Seddon H, Kay A. Glucorticoid resistant asthma: T-lymphocyte steroid metabolism and sensitivity to glucocorticoids and immunosuppressive agents. Eur Resp J 1996;9:2077-86.
26. Collaziol D, Preissler T, Bauer ME. Avaliação da proliferação linfocitária e sensibilidade a glicocorticóides por ensaios colorimétricos. Revista de Medicina da PUCRS 2002; 12: 226-31.
27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
28. Markov AK, Rayburn TS, Talton DS, Netherland DE, Moore C, Heath B, et al. Fructose-1,6-diphosphate alone and in combination with cyclosporine potentiates rat cardiac allograft survival and inhibits lymphocyte proliferation and interleukin-2 expression. Transplantation 2002; 74: 1651-4.
29. Vinegar R, Truax JF, Selph JL, Voelker FA. Pathway of onset, development, and decay of carrageenan pleurisy in the rat. Fed Proc 1982; 41: 2588-95.
30. Di Rosa M, Willoughby DA. Screens for anti-inflammatory drugs. J Pharm Pharmacol 1971; 23: 297-8.
31. Oyanagui Y. Fructose-1,6-diphosphate enhanced oxyradicals and nitric oxide-dependent suppressions by dexamethasone of ischemic and histamine paw edema of mice. Life Sci 1998; 62: 241-9.